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Abstract Little is known about rates and risk factors of sub-
stance use (SU) in individuals with mild to borderline intel-
lectual disabilities (MBID, IQ 50–85). This hinders targeted
prevention and treatment. In this study we assessed SU rates
and risk factors in individuals with MBID in 419 adults (63%
male, average IQ = 66) in 16 Dutch disability services.
Lifetime and current SU, SU picture recognition, knowledge,
attitudes and modeling were assessed with the Substance use
and misuse in Intellectual Disability - Questionnaire (SumID-
Q). Lifetime licit SU (alcohol and tobacco) was 97%, lifetime
illicit SU (predominantly cannabis) was 50%. Current users of
tobacco (62%), alcohol (64%), and cannabis (15%) initiated
SU at a younger age than those who desisted SU (ps < .001).
Participants with mild ID and those with borderline ID did not
differ in SU rates (ps .429–.812), or age at SU initiation (ps
.221–.853). Current licit SU and lifetime illicit SU were relat-
ed to male gender, younger age, and (for smoking and stimu-
lant use) to lack of daytime activities. However, these factors
did not contribute to multivariate models when recognition,
knowledge, attitudes and modeling were added. The models
correctly identified current SU in 84% (smoking) and 74%
(drinking), and lifetime SU in 76% (cannabis) and 84%
(stimulants) of the participants. As almost all participants re-
ported lifetime use of licit, and about half reported lifetime
illicit substance use, systematic screening for substance use,
and development of preventative and treatment interventions
targeted to this group are needed.
Keywords Substance use . Intellectual disability .
Assessment . Risk factors . Prevalence . Epidemiology
Introduction
Individuals with mild to borderline intellectual disability
(MBID) have been identified as a risk group for negative
consequences of substance use (SU), and substance use disor-
der (SUD) (Burgard et al. 2000; Carroll Chapman and Wu
2012; Hassiotis et al. 2011; McGillicuddy 2006; Mcgillivray
and Moore 2001; Van Duijvenbode et al . 2015).
Unfortunately, little is known about SU prevalence and risk
factors in individuals withMBID. This hinders addictionmed-
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icine and MBID services to take preventative actions and im-
plement targeted treatment.
According to the DSM5 (American Psychiatric Association
2013), an intellectual disability (ID) involves 1) impairments of
general mental abilities, that 2) impact adaptive functioning in
the conceptual, social and practical domain, and that 3) occur
during the developmental period. While its severity is based on
(impairments in) adaptive functioning, in the DSM5 text de-
scription the former DSM-IV criterion of an IQ-test score ap-
proximately two standard deviations below the population
mean (i.e., an IQ of 70 or below) is still used. Borderline intel-
lectual functioning is defined as an IQ in the 71–84 range
(American Psychiatric Association 2013). Though the level of
ID may be described as ‘borderline’ (BID) or ‘mild’ (MID, IQ
50–70), in the MBID group a variety of problems accumulate,
including poorer physical and mental health, social disadvan-
tages, limited social support, overrepresentation in the forensic
and mental health system (Lindsay et al. 2013; Wieland and
Zitman 2015), and limited access to services including addic-
tion treatment (Slayter 2010; Van Duijvenbode et al. 2015).
Rates of SU(D) in MBID vary greatly across studies, de-
pending on sampling characteristics (Carroll Chapman and
Wu 2012; Van Duijvenbode et al. 2015). Several demograph-
ic, contextual and diagnostic factors have been associatedwith
SU(D) in MBID, such as younger than 30 years old, male, no
structured daytime activities (To et al. 2014; VanDerNagel
et al. 2011a), and living independently (Taggart et al. 2006;
To et al. 2014). Furthermore, SU(D) in MBID is associated
with psychiatric or behavioral (Chaplin et al. 2011; Didden
et al. 2009) and forensic problems (Crocker et al. 2007;
Hassiotis et al. 2011; Mcgillivray et al. 2015). For instance,
among 39 patients with MBID in an inpatient treatment facil-
ity, 28% abused alcohol, and 36% drugs (Didden et al. 2009).
In a psychiatric outpatient facility (n = 115), 17% alcohol
misuse, 6% cannabis misuse and 3% cocaine misuse was
found (Chaplin et al. 2011). In offenders with ID, several
studies found SUD rates of approximately 60% (Crocker
et al. 2007; Hassiotis et al. 2011; Mcgillivray et al. 2015).
On the other hand, in several community based samples only
1% had a SUD diagnosis (Cooper et al. 2007; Taggart et al.
2006). As to SU, in a Belgian study in 123 individuals with
MBID living independently, 48% smoked, 46% drank alco-
hol, and 2% used illicit substances in the past month (Swerts
et al. 2017). Smoking rates in other community based samples
of adults with ID, were much lower, for instance 1.9% in
social education centers (Whitaker and Hughes 2003), and
9.3% in attenders at day care centers (Taylor et al. 2004). In
adolescents with MBID, however, current smoking rates var-
ied from 14% (Emerson and Turnbull 2005) to 34% (Žunić-
Pavlović et al. 2013) and in forensic ID samples smoking rates
are reported to be up to 60% (Chester et al. 2011).
One of the challenges to assess rates of SU(D) in individ-
uals with MBID is the lack of valid instruments. While self-
reported SU in the general population is associated with high
levels of under-report (see e.g., Fendrich et al. 2004), self-
report in individuals with MBID may be even more biased,
especially when mainstream questionnaires are used
(McGillicuddy 2006; VanDerNagel et al. 2013; Van
Duijvenbode et al. 2015). However, the Substance use and
misuse in intellectual disability – Questionnaire (SumID-Q,
VanDerNagel et al. 2011b, 2013) – specifically developed to
assess SU in MBID– had moderate to almost perfect agree-
ment with biomarker analysis, and low levels of under-report
(VanDerNagel et al. 2017). This may be the result of its step-
by-step non-confrontational approach, in which SU picture
recognition, knowledge, attitudes, and modeling are assessed
before participants’ SU is discussed. Based on previous stud-
ies, it is unclear if these factors are associated with SU status.
For instance, though alcohol-related knowledge was poor in
people with mild ID compared to non-ID groups (McCusker
et al. 1993), alcohol and tobacco related knowledge in other
studies were not associated with drinking and smoking in
MBID (Swerts et al. 2017, Whitaker and Hughes 2003).
Living together with smokers, however, was associated with
smoking in two studies with children (Emerson et al. 2016)
and adults (Whitaker and Hughes 2003) with ID. Knowledge
about the relations between demographic, contextual, diag-
nostic, and SU related factors may contribute to an effective
assessment, as well as to prevention and targeted treatment of
SU(D) in this group. Furthermore, the majority of these stud-
ies were conducted abroad, and may not reflect the situation in
the Netherlands, as both tobacco-, alcohol-, and illicit drug
policies as well ID services vary between countries.
This study therefore used the SumID-Q to assess SU rates
and risks in individuals with MBID who receive care from
Dutch disability services. More specifically this cross-
sectional study aimed to determine lifetime and past month
rates of alcohol, tobacco, cannabis, and stimulant use; to as-
sess whether age at initiation of SU differs between a) current
users, versus participants who desisted SU, and b) participants
with mild ID (IQ 50–70) versus borderline ID (IQ 71–84); to
identify demographical, contextual, and diagnostic risk factors
for SU; and to assess the contribution of SU related factors
(i.e., SU recognition, knowledge, attitude, and modeling) to a
model for SU based on demographical, contextual, and diag-
nostic factors alone.
Method
Participants
In 2010 and 2011, individuals from 22 organizations of the
Dutch Association of Healthcare Providers for People with
Disabilities [Vereniging Gehandicaptenzorg Nederland,
VGN] were invited to participate. These organizations provide
284 Adv Neurodev Disord (2017) 1:283–293
a range of services, including supported living, institutional
living, day-care centers, supported employment, and outpa-
tient services. Five organizations declined to participate, and
one was unable to fulfill the intention to participate. The re-
maining 16 organizations were asked to randomly select 10%
of individuals with MBID in their facilities, and provide their
contact details for recruitment purposes. However, several or-
ganizations could not or would not (because of privacy issues)
provide a list based on level of ID, and therefore recruited
participants themselves.
Individuals were eligible for participation if they 1) re-
ceived care from one of these organizations, 2) were ≥18 years
old, 3) had MBID (IQ 50–85), and 4) had no such language or
communication problems that participation was unfeasible.
A total of 600 individuals met our inclusion criteria, client
representatives withheld consent in three individuals with a
history of SUD, and in 26 individuals for other reasons, 147
individuals gave no informed consent, and data from five
individuals were removed because of premature termination
of the interview. Thus, 419 participants (70%) were included
in the sample (Table 1).
Procedure
Participants were visited at a venue of their choice by a trained
research assistant who explained the study procedures using a
DVD presentation and an illustrated leaflet with an easy to
read text. Written informed consent was obtained from both
the client and his or her (legal) representative. Participants
received a small gift (worth approximately €2.50 / $2.70) after
the interview.
Measures
Demographic, Contextual and Diagnostic Characteristics
Data on demographic (date of birth, ethnicity, marital status),
contextual (living arrangement, daytime activities), and diag-
nostic (BID, MID, full-scale IQ [TIQ]) characteristics were
obtained from participants’ professional caregivers.
Substance Use
The Substance use and misuse in Intellectual Disability -
Questionnaire (SumID-Q) (VanDerNagel et al. 2011b, 2013,
2017) assesses lifetime and past month (recent) SU. It is a
structured interview that incorporates several strategies to re-
duce bias in self-report in individuals with MBID, including
1) adaptation of item structure and wording, 2) use of visual
aids, and 3) a step by step non-confrontational approach.
Administration of the SumID-Q takes 45 to 60 min. It starts
with assessing participants’ familiarity with substances (to-
bacco, alcohol, cannabis, stimulants [i.e., cocaine and
amphetamines] and other illicit drugs) by showing substance
related pictures from a standardized set, asking for each pic-
ture ‘What is this?’. In the case of an incorrect response, the
interviewer assesses if the participant can provide an adequate
description of the substance when the mainstream name of the
substance is presented (‘What is weed?’). If the participant can
neither identify any of the pictures related to a specific sub-
stance, nor describe it correctly, he or she is classified as not
being familiar with this substance, and no further questions
about this substance are asked. For each of the substances
correctly recognized, further questions on substance knowl-
edge and attitudes, and SU modeling are asked. Then, the
participant is asked for each substance ‘Did you ever use this?’
(lifetime use; yes/no response format); and, if yes, ‘Once or
more often?’ and ‘How old were you the first time?’ For the
four substances most commonly used by individuals with
MBID in the Netherlands (i.e., tobacco, alcohol, cannabis,
and stimulants) (Van Laar and Van Ooyen-Houben 2016),
SU patterns, and current SU is assessed. Reliability of the
subscales in this study was good for picture recognition
Table 1 Participant Characteristics (N = 419)
Variable (n) Mean (SD) n %
Gender
Male 264 63.0
Age (404) 34.5 (14.4)
Marital status (404)
Married 23 5.7
Divorced 24 5.9
Widowed 6 1.5
Other 351 83.9
Living arrangement (408)
Spousea 34 8.1
With children 6 1.4
Other family 12 2.9
Single 166 39.6
Group 190 45.3
Level of ID
Mild 273 65.2
Borderline 146 34.8
IQ (255) 66.1 (9.3)
Etnicity (417)
Caucasian 383 91.4
Other 34 8.1
ID Service
Institutional grounds 66 15.8
Community facility 219 52.3
Otherb 134 32.0
a Participants living with a spouse, with or without children
b Includes supported living and case coordination services
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(α = .87), SU knowledge (α = .80), SU attitudes (α = .82), and
acceptable for SU modeling (α = .76).
Data Analyses
Data were analyzed with SPSS (version 21). For each sub-
stance, composite scores were calculated for SU recognition
(number of pictures correctly identified, range 0–8), knowl-
edge (number of correct answers, maximum score = 8), pos-
itive attitude towards SU (maximum score = 10), and SU
modeling (maximum = 15).
To determine lifetime and current SU rates, we calculated
percentages of participants who used ‘never’/‘once’/‘more
than once’, and in the past month.
To assess whether age at initial SU differed between a)
current users versus participants who desisted SU (i.e., partic-
ipants who had used a substance at some time in their lives,
but not in the last month), and b) participants withMID versus
BID, we used Kaplan Meier curves, and the log rank test to
compare survival times to age at initial use.
To identify demographical, contextual, and diagnostic risk
factors for current tobacco and alcohol, and for lifetime can-
nabis and stimulant use, we calculated associations between
these variables and SU status. For independent variables age
and IQ, quartiles were used. Variables with univariate p values
< .20 were entered into a stepwise forward multiple logistic
regression analysis comparing current users with non-users
(for alcohol and tobacco use), and lifetime users with non-
users (cannabis and stimulants), and they remained in the
model if this resulted in a significant (p < .05) change in -
2Loglikelihood.
To assess the contribution of SU recognition, knowledge,
attitudes, and modeling to this model, we first assessed the
univariate associations between these factors (divided in quar-
tiles, or – if impossible due to skewed data – in two or three
groups) and SU status within the subgroup of participants who
were familiar with the substance of interest (recognition
score ≥ 1). Then, in a stepwise forward procedure, these var-
iables were added to the model based on demographical, con-
textual, and diagnostic variables alone, if univariate p values
were < .20, and they remained in the model if this resulted in a
significant (p < .05) change in - 2Loglikelihood.
Results
SU Rates
Almost all participants (n = 407, 97%) had used substances
licit in the Netherlands (alcohol and tobacco) at least once in
their lives, and a large proportion (n = 208, 50%) had used at
least once illicit substances (Table 2.). No significant
differences in lifetime use (ps between .429 and .742) were
found between participants with MID versus those with BID.
In the past month, only 81 participants (19%) had not used
substances at all. About a third (n = 142) used one substance,
mainly tobacco (n = 64, 15%), or alcohol (n = 77, 18%).
Almost half of our participants (n = 196, 47%) used more than
one substance, mainly tobacco and alcohol (n = 133, 32%) or
tobacco, alcohol and cannabis (n = 50, 12%). In total, 15%
(n = 64) used cannabis or stimulants. No significant differ-
ences in current SU rates (ps between .558 and .812) were
found between participants with MID versus BID.
Age at Initial SU
SU initiation occurred mainly during adolescence, though
several participants started to use tobacco and alcohol at a
much younger age (Fig. 1). Cannabis and stimulant use were
typically initiated later in adolescence (Fig. 1).
Current smokers initiated smoking at a younger age than
participants who desisted smoking (median = 13 years,
IQR = 12–16 years, versus median = 16 years, IQR = 13–
18 years; χ2(1) = 11.97, p < .001). Similarly, current drinkers
initiated drinking at a younger age (median = 16 years,
IQR = 14–18 years) compared to those who desisted (medi-
an = 17 years, IQR = 15–17 years; χ2(1) = 12.02, p < .001),
and current users of cannabis started using at a younger age
(median = 15 years, IQR = 13–16 years) than those who
desisted (median = 17 years, IQR = 16–20 years;
χ2(1) = 16.51, p < .001). No significant differences in age
of initial use were found between current stimulant users (me-
dian = 24 years, IQR = 17–26) and participants who desisted
(median = 18 years, IQR = 16–21 years; χ2(1) = 1.10,
p = .293). Median survival time to initial use did not differ
significantly for any substance between participants with mild
ID and those with borderline ID (ps between .221 and .853).
Univariate and Multivariate Demographic, Contextual
and Diagnostic Risk Factors
Univariate and multivariate analyses of the demographic, con-
textual, and diagnostic characteristics versus current tobacco
and alcohol use are presented in Table 3. Current tobacco use
was significantly higher in males, and in those with a lack of
structured daytime activities. Current alcohol use was signif-
icantly higher inmales, and lower in the oldest two quartiles of
participants (age > 31.9 years) compared to the youngest quar-
tile (age < 21.6 years).
The multivariate model for current tobacco use contained
male gender and lack of daytime activities. Though this model
classified 63% of the participants correctly, it explained only a
small proportion of smoking status variance (Table 3).
Similarly, the final model for alcohol use, based on gender
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and age, explained little variance, but classified 65% of the
participants correctly.
Lifetime use of both cannabis and stimulant use were
significantly related to male gender and younger age, and
in addition, lifetime stimulant use was significantly asso-
ciated with lack of daytime activities (Table 4). The mul-
tivariate model for lifetime cannabis use based on age and
gender classified 61% of the participants correctly. For
lifetime stimulant use, male gender, younger age and lack
of daytime activities contributed to the model, classifying
79% of the participants correctly. Compared to the models
for current tobacco and alcohol use, these variables ex-
plained slightly more, but still small proportions of SU
status variation.
SU Picture Recognition, Knowledge, Attitudes
and Modeling, as Risk Factors for SU
For current tobacco and alcohol use, SU picture recognition,
attitude, and modeling, but not knowledge were related to
current smoking and drinking (Table 5). These factors also
remained significant in the multivariate tobacco model, which
Table 2 Self-reported lifetime and past month SU rates & ages of onset
Lifetime use Current use Age of initial SU (years)
Never Once More than oncea Yes
n % n % n % N % Mean SD Range
Tobacco 71 16.9 35 8.4 313 74.7 258 61.6 14.1 3.4 5–27
Alcohol 26 6.2 22 5.3 371 88.5 267 63.7 16.2 4.5 5–40
Cannabis 222 53.0 48 11.5 149 35.6 61 14.6 18.1 6.8 8–50
Stimulants 353 84.2 15 3.6 51 12.2 5 1.2 19.8 5.9 11–40
Ecstasy 345 88.5 15 3.6 33 7.9 18.6 4.7 11–37
Non-prescribed opioids 401 95.7 5 1.2 13 3.1 22.6 8.1 11–40
Non-prescribed BZD 400 95.5 4 1.0 15 3.6 25.2 11.4 13–44
LSD 407 97.1 6 1.4 6 1.4 17.9 3.9 11–25
Psychedelic mushrooms 386 92.1 17 4.1 16 3.8 18.6 4.9 11–40
GHB 404 96.4 9 2.1 6 1.4 18.9 3.9 12–25
SD = Standard deviation, BZD = benzodiazepines, LSD = Lysergic acid diethylamide, GHB = γ-Hydroxybutyric acid
a Includes participants with current SU
Fig. 1 Age at initial use of
tobacco, alcohol, cannabis and
stimulants
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explained between 43% and 58% of the variance of smoking
(Table 5), and correctly identified smoking status in 84% of
the participants.
For alcohol use, picture recognition did not contribute sig-
nificantly to the model based on gender, age, and attitude and
modeling. This model predicted between 19% and 26% of the
variance in current alcohol use, and correctly identified drink-
ing status in 73% of the participants. Tobacco and alcohol
related knowledge did not contribute significantly to the mul-
tivariate models (Table 5).
Participants who did not recognize any of the cannabis
(n = 23) or stimulant related pictures (n = 97) were excluded
from the SU related analyses of these substances. For cannabis
and stimulants, picture recognition, knowledge, attitude, and
modeling contributed significantly to both the univariate as-
sociations and the multivariate model (Table 6). The models
explained between 36% and 47% of lifetime cannabis use
status, and between 36% and 54% of stimulant use, and cor-
rectly identified lifetime cannabis use in 76%, and stimulant
use in 84% of the participants.
Table 3 Univariate andmultivariate associations between demographic and contextual characteristics, level of ID; and current tobacco and alcohol use
Tobacco Univariate Multivariate model
β OR 95% CI OR β OR 95% CI OR
Constant .078
Demographic
Male .53** 1.71 1.14 2.56 .57** 1.78 1.16 2.72
Age in years (Q1) 1
Q2 .17 1.19 .67 2.12
Q3 <.01 1.0 .57 1.77
Q4 −.25 .78 .45 1.37
Contextual
Independent living −.21 .81 .53 1.24
No daytime activities .71* 2.04 1.03 4.04 .76* 2.14 1.07 4.28
Intellectual functioning
Mild ID −.09 .91 .60 1.38
TIQ (Q1), (n = 255) 1
Q2 .05 1.05 .53 2.09
Q3 .33 1.38 .67 2.85
Q4 .25 1.28 .62 2.66
Alcohol
Constant
Demographic
Male .40 1.49 .99 2.24 .39 1.47 .96 2.26
Age in years (Q1) 1 1
Q2 −.35 .70 .38 1.30 −.39 .68 .37 1.25
Q3 −.64* .53 .29 .96 −.69* .50 .28 .92
Q4 −.76* .47 .26 .85 −.80** .45 .24 .82
Contextual
Independent living .21 1.24 .80 1.90
No daytime activities .21 1.23 .65 2.31
Intellectual functioning
Mild ID −.17 .88 .58 1.34
TIQ (Q1), (n = 255) 1
Q2 .34 1.41 .70 2.83
Q3 .39 1.47 .71 3.03
Q4 .72 2.06 .96 4.41
Q1 = first quartile; OR = Odds Ratio, ID = intellectual disability, TIQ = full scale IQ, * p < .05, ** p < .01, *** p < .001Multivariate model for current
tobacco use: χ2 (2, n = 387) = 11.12, p = .004. Cox & Snell R2 = .029, Nagelkerke R2 = .040
Multivariate model for current alcohol use: χ2 (4, n = 403) = 10.68, p = .001. Cox & Snell R2 = 0.026, Nagelkerke R2 = 0.036
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Discussion
A lack of knowledge about SU rates and risk factors in indi-
viduals with MBID in the Netherlands hinders targeted pre-
vention and interventions. Available studies are often limited
to highly selected samples, report highly divergent rates, and
provide limited knowledge on demographical, contextual, di-
agnostic and other risk factors. Furthermore, it is unclear
whether international studies are relevant for the situation in
the Netherlands. Therefore, we assessed SU rates and risks in
individuals with MBID in several Dutch ID services.
In our sample, the rates of current smoking (62%), current
cannabis and other illicit drug use (15%), but not drinking
(64%) were very high, given the SU rates in the Dutch general
population (past month tobacco use ≈ 25%, alcohol use ≈
77%, cannabis use ≈ 5%, stimulant use <1%) (Van Laar and
Table 4 Univariate and multivariate associations between demographic and contextual characteristics, level of ID; and lifetime cannabis and stimulant
use
Cannabis Univariate Multivariate model
β OR 95% CI OR β OR 95% CI OR
Constant .10
Demographic
Male .44* 1.55 1.03 2.32 .34 1.41 .92 2.16
Age in years (Q1) 1 1
Q2 .14 1.15 .65 2.04 .11 1.12 .63 1.98
Q3 −.35 .71 .40 1.24 −.38 .68 .39 1.20
Q4 1.18*** .31 .17 .56 −1.21*** .30 .16 .55
Contextual
Independent living −.23 .79 .52 1.21
No daytime activities .39 1.47 .80 2.70
Intellectual Functioning
Mild ID −.07 .93 .62 1.40
TIQ, (Q1), (n = 255) 1
Q2 .44 1.55 .78 3.10
Q3 .43 1.53 .75 3.14
Q4 .68 1.97 .95 4.08
Stimulants
Constant −2.73
Demographic
Male 1.36*** 3.90 1.93 7.91 1.34*** 3.82 1.83 7.98
Age in years (Q1) * 1 1
Q2 . .53 1.69 .82 3.47 .42 1.52 .72 3.22
Q3 .28 1.33 .63 2.79 −.02 .98 .45 2.16
Q4 −.85 .43 .17 1.10 −1.04* .35 .13 .95
Contextual
Independent living −.45 .64 .35 1.17
No daytime activities .83* 2.29 1.15 4.55 1.15** 3.15 1.48 6.69
Intellectual Functioning
Mild ID .08 1.08 .62 1.89
TIQ, (Q1), (n = 255) 1
Q2 .31 1.36 .53 3.47
Q3 .35 1.42 .54 3.70
Q4 .41 1.51 .58 3.94
Q1 = first quartile; OR = Odds Ratio, ID = intellectual disability, TIQ = full scale IQ, * p < .05, ** p < .01, *** p < .001
Multivariate model for lifetime cannabis use: χ2 (4, n = 391) = 25.76, p < .001. Cox & Snell R2 = .064, Nagelkerke R2 = .085
Multivariate model for lifetime stimulant use: χ2 (5, n = 379) = 32.42, p < .001. Cox & Snell R2 = 0.082, Nagelkerke R2 = .139
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Van Ooyen-Houben 2016). Compared to studies in the MBID
population (Carroll Chapman and Wu 2012; Emerson and
Turnbull 2005; McGillicuddy 2006; Swerts et al. 2017;
Taylor et al. 2004; Whitaker and Hughes 2003; Žunić-
Pavlović et al. 2013), including the Flemish SumID-Q study
(Swerts et al. 2017), all SU rates seem rather high, but illicit
Table 5 Univariate and multivariate associations between demographic, contextual characteristics, SU related measures; and current smoking and
drinking in participants familiar with the substance of interest (n = 419)
Tobacco Univariate Multivariate model
β OR 95% CI Β OR 95% CI
Constant −3.18
Variables from step 1
Male gender .53** 1.71 1.14 2.56 .56 1.75 .94 3.24
No daytime activities .71* 2.04 1.03 4.04 −.81 .45 .18 1.13
SU related measurements
Recognitiona 1.39*** 4.02 2.10 7.69 1.64*** 5.14 2.00 13.20
Knowledge (Q1) 1
Q2 .37 1.45 .63 3.35
Q3 .17 1.19 .53 2.64
Q4 −.19 .83 .36 1.91
Attitude (score 0–1) 1
Score 2–3 2.48*** 11.92 6.75 21.05 2.54*** 12.65 6.59 24.30
Score ≥ 4 4.46*** 86.14 36.07 205.75 4.17*** 64.60 25.82 161.64
Modeling (Q1) 1 1
Q2 .69** 2.00 1.22 3.29 .73* 2.08 1.02 4.25
Q3 1.42*** 4.13 2.24 7.61 1.28** 3.58 1.46 8.76
Q4 1.62*** 5.07 2.58 9.95 1.15* 3.18 1.23 8.25
Alcohol
Constant −1.22
Variables from step 1
Male gender .40 1.49 .99 2.24 .16 1.17 .72 1.90
Age (Q1) 1 1
Q2 −.35 .70 .38 1.30 .52 1.68 .84 3.35
Q3 −.64* .53 .29 .96 .12 1.12 .58 2.18
Q4 −.76* .47 .26 .85 −.09 .91 .49 1.72
SU related measurements
Recognitiona .79** 2.21 1.30 3.78
Knowledgeb .38 1.47 .98 2.20
Attitude (Q1) 1 1
Q2 1.11*** 3.02 1.72 5.32 1.16*** 3.20 1.72 5.94
Q3 1.64*** 5.15 2.81 9.45 1.55*** 4.70 2.42 9.12
Q4 2.08*** 7.97 4.26 14.91 1.88*** 6.57 3.39 12.71
Modeling (Q1) 1 1
Q2 .78** 2.17 1.29 3.656 .81** 2.24 1.26 4.01
Q3 1.37*** 3.94 2.08 7.490 1.15*** 3.15 1.54 6.46
Q4 1.57*** 4.80 2.63 8.760 1.25*** 3.48 1.75 6.92
Q1 = first quartile; OR = Odds Ratio, * p < .05, ** p < .01, *** p < .001
ID = intellectual disability, TIQ = full scale IQ, SU = Substance Use
a Participants with below maximum recognition score versus participants with maximum score
b Participants with knowledge score 0–5 versus >5Expanded model for current tobacco use: χ2 (7, n = 385) = 215.14, p < .001. Cox & Snell R2 = .428,
Nagelkerke R2 = .584
Expanded model for current alcohol use: χ2 (10, n = 399) = 83.16, p < .001. Cox & Snell R2 = .188, Nagelkerke R2 = .259
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Table 6 Univariate and multivariate associations between demographic, contextual characteristics, SU related measures; and lifetime cannabis and
stimulant use in participants with ID who are familiar with substance of interest (cannabis n = 396, stimulants n = 322)
Cannabis Univariate Multivariate model
β OR 95% CI Β OR 95% CI
Constant −3.80
Variables from step 1
Male gender .39 1.48 .98 2.25 −.26 .77 .43 1.36
Age (Q1) 1 1
Q2 .17 1.19 .67 2.11 −.27 .76 .32 1.81
Q3 −.35 .70 .40 1.23 .50 1.66 .72 3.80
Q4 −.97** .38 .21 .70 −.31 .73 .33 1.65
SU related measurements
Recognitiona 1.84*** 6.28 4.03 9.80 1.20*** 3.33 1.86 5.98
Knowledge (Q1) 1 1
Q2 1.42*** 4.14 2.24 7.67 1.10** 3.01 1.42 6.40
Q3 2.00*** 7.41 3.76 14.59 1.34*** 3.81 1.68 8.64
Q4 2.95*** 19.19 8.85 41.61 2.11*** 8.26 3.22 21.21
Attitude (score 0–1) 1 1
Score 2 1.44*** 4.22 2.59 6.86 1.33*** 3.79 2.09 6.88
Score ≥ 3 2.90*** 18.26 8.74 38.15 2.19*** 8.94 3.63 22.03
Modeling (Q1) 1 1
Q2 .37 1.45 .75 2.79 −.13 .88 .40 1.94
Q3 1.27*** 3.55 2.07 6.10 .61 1.85 .93 3.65
Q4 2.18*** 8.86 4.37 18.00 1.04* 2.84 1.17 6.89
Stimulants
Constant −9.94
Variables from step 1
Male gender 1.15** 3.14 1.53 6.45 .33 1.39 .52 3.69
Age (Q1) 1 1
Q2 .49 1.64 .78 3.43 1.20 3.33 .77 14.39
Q3 .28 1.33 .62 2.85 1.21 3.35 .84 13.34
Q4 −.76 .47 .18 1.22 .69 1.99 .50 8.03
No daytime activities .87* 2.38 1.15 4.91 .80 2.22 .75 6.56
SU related measurements
Recognition (Q1) 1 1
Q2 1.71* 5.51 1.11 27.39 1.98 7.21 .75 69.67
Q3 2.74*** 15.58 3.47 68.77 2.87** 17.68 2.10 148.92
Q4 3.82*** 45.60 10.50 198.12 3.76*** 42.86 4.95 371.41
Knowledge (Q1) 1 1
Q2 2.80** 16.61 2.18 126.57 2.65* 14.12 1.37 145.98
Q3 3.02** 20.51 2.67 157.70 2.45* 11.58 1.15 117.04
Q4 3.78*** 43.59 5.68 334.29 2.81* 16.52 1.56 174.84
Attitude (score 0) 1 1
Score 1 1.27*** 3.56 1.78 7.15 .97* 2.63 1.01 6.89
Score ≥ 2 2.51*** 12.32 5.85 25.91 2.72*** 15.14 4.34 52.77
Modeling (No/Yes) 1.59*** 4.90 2.71 8.88
Q1 = first quartile; OR = Odds Ratio, * p < .05, ** p < .01, *** p < .001, ID = intellectual disability, TIQ = full scale IQ, SU = Substance Use
a Participants with below maximum recognition score versus participants with maximum score
Expanded model ifetime cannabis use: χ 2 (13, n = 347) = 151.99, p < .001. Cox & Snell R2 = 0.355, Nagelkerke R2 = .474
Expanded model lifetime stimulant use: χ2 (14, n = 246) = 111.36, p < .001. Cox & Snell R2 = 0.364, Nagelkerke R2 = .543
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drug use in our study stands out. This may be explained by
higher levels of use and willingness to disclose such use, re-
lated the Dutch cannabis policies (i.e., users are seldomly
prosecuted) that mislead some individuals withMBID to think
cannabis use is legal in the Netherlands (VanDerNagel et al.
2013, 2017). While sampling differences may contribute to
the different rates between the Dutch and Flemish SumID
studies, the exclusion of individuals with BID in the latter
does not explain our higher rates since we did not find differ-
ences between BID and MID in SU rates, and for that matter
neither in age of initial use.
As described in other populations (see e.g., Carroll
Chapman and Wu 2012; McGillicuddy 2006), SU initiation
occurred typically in adolescence, but several participants ini-
tiated SU at primary school age. Participants whowere current
users, had started at younger ages than those who desisted,
corroborating findings in individuals without MBID (Bolland
et al. 2016; Nelson et al. 2015; Prince van Leeuwen et al.
2014). Though gender, age and lack of daytime activities were
associated with SU, independent living and level of ID (MID
versus BID) were not, contrary to suggestions from other
studies (e.g., To et al. 2014; Taggart et al. 2006). Moreover,
demographic and contextual factors were of little relevance to
the final models in which substance picture recognition,
knowledge, attitude and modeling were added. Substance re-
lated knowledge was significantly higher in users compared to
non-users of illicit substances, but not in users of licit sub-
stances, as was found in the Flemish SumID-Q study
(Swerts et al. 2017). For all substances, substance related pos-
itive attitudes and SU modeling were associated with an in-
crease in SU likelihood, as previous studies in MBID found
for smoking and drinking (Emerson et al. 2016; Swerts et al.
2017; Whitaker and Hughes 2003).
Limitations and Future Research Directions
Since this study had a cross-sectional design, there is a risk of
recall bias and causality between risk factors and SU status
cannot be established. For instance, SU knowledge, and pos-
itive SU attitudes could lead to SU, but SU in turn can increase
SU knowledge and positive attitudes. In addition, though this
study concerns a relatively unselected and relatively large
sample of individuals with MBID receiving care from a vari-
ety of settings, we cannot claim that this sample is represen-
tative of MBID population. Furthermore, since clustered ran-
domized sampling proved to be unfeasible given the divergent
ways participating organizations were sized and structured,
and because of the lack of non-response analysis, selection
bias cannot be ruled out.
Thus, prospective studies in cohorts of individuals with
MBID who have not initiated in SU are needed. Given the
young age at SU initiation in some of our participants, as well
as those in other Dutch studies (e.g. Kiewik et al. 2016), these
studies best start with samples of primary school aged partic-
ipants. Since we did not distinguish between problematic SU,
and non-problematic SU, further studies will also need to as-
sess if and how risk factors are related to SUD. Given the high
– and from a health and social perspective alarming – SU rates
in our study, preventative actions that are currently in place
apparently are insufficient for individuals with MBID. This
calls for increased efforts from addiction facilities and ID ser-
vices to develop, implement and study effective interventions.
These interventions should target variables such as SU related
attitudes, and SUmodeling, including peer influences but also
modeling by staff members. Since demographic, contextual
and diagnostic account only for a small part of the variance
in SU status, such interventions need to be available to all
individuals with MBID. In addition, in order to identify (risk
factors of) SU timely, a case-by-case approach using measure-
ments such as the SumID-Q is needed.
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